Barbiturates FirstVue™ Drug Screen
The Barbiturates FirstVue™ Drug Screen is a rapid, qualitative, competitive binding immunoassay for the determination of Barbiturates and its metabolites in urine at or above the cutoff level of 300 ng/ml.
The Barbiturates FirstVue™ Drug Screen is a rapid, qualitative, competitive binding immunoassay for the determination of Barbiturates and its metabolites in urine at or above the cutoff level of 300 ng/ml.
Slang Term(s): Barbs, barbies, sleepers, blue bullets, blues, pink ladies, pinks, block busters
Screening Cut-off in Urine: 300 ng/mL
Drug Information:
Barbiturates are central nervous system depressants. They are used therapeutically as sedatives, hypnotics, and anticonvulsants. Barbiturates are almost always taken orally as capsules or tablets. The effects resemble those of intoxication with alcohol. Chronic use of barbiturates leads to tolerance and physical dependence.
Short acting Barbiturates taken at 400 mg/day for 2-3 months can produce a clinically significant degree of physical dependence. Withdrawal symptoms experienced during periods of drug abstinence can be severe enough to cause death.
Only a small amount (less than 5%) of most Barbiturates are excreted unaltered in the urine.